100 Washington Boulevard
Stamford, CT 06902
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that re-prioritizes promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer. Since its launch in 2017, SpringWorks has worked to identify, re-prioritize, and advance promising science, beginning with licensed clinical therapies from Pfizer Inc. SpringWorks pioneers efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the full potential of science for patients.
SpringWorks Therapeutics is advancing a pipeline of standalone and combination therapies with an initial focus on severe rare diseases and oncology. Our two lead development programs will be entering pivotal studies in the first half of 2019: nirogacestat, a gamma secretase inhibitor for the treatment of desmoid tumors, and PD-0325901, a MEK 1/2 inhibitor for neurofibromatosis type 1 patients with plexiform neurofibromas. PD-0325901 also holds promise as the backbone for combination therapies to treat metastatic solid tumors. Our pipeline also includes two earlier-stage assets for neurological and hematological conditions.